CRISPR Therapeutics AG EPS Ratio 2011-2026 | CRSP

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio CRISPR Therapeutics AG

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-6.47	-4.34	-1.94	-8.36	4.97	-5.29	1.23	-3.44	-1.71	-1.89	-5.06	1.97	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
4.97	-8.36	-2.53

Quarterly EPS Ratio CRISPR Therapeutics AG

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-1.17	-2.4	-1.58	-	-1.01	-1.49	-1.43	-	-1.41	-0.98	-0.67	-	-2.24	-2.4	-2.32	-	-1.67	10	-1.51	-1.5	-1.32	-1.3	-1.15	0.53	2.52	-1.01	-0.93	-0.92	-1.07	-0.82	-0.62	-	-0.62	-0.56	-0.54	0.43	-2.77	-3.15	-1.53	-2.22	-1.15	-0.8	-0.91	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
10	-3.15	-0.886

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	-0.78	$ 0.79	-1.15 %	$ 4.31 M	China
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
AbCellera Biologics ABCL	-0.49	$ 3.49	0.58 %	$ 1.04 B	Canada
Frequency Therapeutics FREQ	-12.5	-	-	$ 528 M	USA
argenx SE ARGX	-7.99	$ 700.45	-1.19 %	$ 25 B	Niderland
I-Mab IMAB	-7.66	-	-	$ 866 M	China
AgeX Therapeutics AGE	-13.7	-	-10.17 %	$ 12.2 K	USA
Alterity Therapeutics Limited ATHE	-0.53	$ 3.6	1.41 %	$ 8.66 B	Australia
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Grifols, S.A. GRFS	0.28	$ 7.81	-2.01 %	$ 6.83 B	Spain
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Ascendis Pharma A/S ASND	-8.28	$ 225.98	-1.32 %	$ 5 B	Danmark
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
ADC Therapeutics SA ADCT	-3.77	$ 4.13	-5.06 %	$ 105 M	Schweiz
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Allena Pharmaceuticals ALNA	-0.72	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	-3.51	-	10.36 %	$ 9.8 M	USA
BioCardia BCDA	-0.55	$ 1.26	-0.79 %	$ 26.7 M	USA
AlloVir ALVR	-11.7	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Anika Therapeutics ANIK	-5.64	$ 14.2	-0.7 %	$ 208 M	USA
Aptose Biosciences APTO	-36.4	-	-45.71 %	$ 1.2 M	Canada
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
Athersys ATHX	-0.39	-	3.77 %	$ 22.4 M	USA
BioNTech SE BNTX	42.2	$ 91.19	1.21 %	$ 27.2 B	Germany
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	-15.8	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-0.86	$ 1.44	-1.37 %	$ 367 M	Britain
Arcturus Therapeutics Holdings ARCT	-2.4	$ 6.68	-4.57 %	$ 183 M	Israel
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
AVEO Pharmaceuticals AVEO	-1.63	-	-	$ 521 M	USA
Burford Capital Limited BUR	75.3	$ 7.92	1.67 %	$ 1.31 B	Britain
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-2.16	$ 2.54	-5.22 %	$ 16 M	USA
Certara CERT	-0.01	$ 6.67	1.6 %	$ 1.07 B	USA
Athira Pharma ATHA	-2.52	-	-	$ 269 M	USA
Can-Fite BioPharma Ltd. CANF	-0.01	$ 3.6	-4.0 %	$ 7.83 B	Israel
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Aravive ARAV	-2.1	-	-13.39 %	$ 1.45 M	USA
Brainstorm Cell Therapeutics BCLI	-2.31	-	-2.5 %	$ 5.88 M	USA